Effectiveness of the XBB.1.5 COVID-19 vaccines. Living Evidence Synthesis 21.3

Related Organizations

Table of Contents

• Effectiveness of the XBB.1.5 COVID-19 vaccines 1
• Living Evidence Synthesis 21 1
• Appendix 1a Summary of Included Studies new studies in blue 1
• Reference author year with URL 1
• Methods Key findings Implications ROBINS- I 1
• Relative VE 95 CI against COVID-19 related hospitalisations 1
• Relative VE 95 CI against COVID-19 related death 2
• Relative VE 95 CI against COVID-19 related ED or UC visits 2
• Relative VE 95 CI against COVID-19 related hospitalisations 3
• Relative VE 95 CI against COVID-19 related outpatient visits 4
• Relative VE 95 CI against COVID-19 related ED or UC visits 4
• Relative VE 95 CI against COVID-19 related hospitalisations 5
• HR against hospitalisation 6
• Relative VE 95 CI against positive test 6
• Positive test with symptomatic infection 7
• Participants who received a bivalent mRNA booster in autumn 2022 COVID-19 vaccination campaign and XBB.1.5 variant adapted vaccine compared to these without XBB.1.5 variant adapted vaccine 7
• Infection Status compared to individuals who had no prior infection 7
• No prior infection 7
• Infection 1 year ago 7
• Infection 1 year ago 7
• Relative VE 95 CI against COVID-19 related 7
• Relative VE 95 CI against COVID-19 related hospitalisations 8
• Relative VE 95 CI against medically attended symptomatic COVID-19 9
• Relative VE 95 CI 14 days after receiving the XBB.1.5 vaccine against medically attended symptomatic laboratory confirmed COVID-19 infection compared to 10
• OR 95 CI against hospitalisation 11
• OR 95 CI against COVID related emergency departmenturgent care ED or UC visits 13
• OR 95 CI against medically attended COVID infections 14
• Relative VE 95 CI against hospitalisation 15
• References 16
• Appendix 1b Summary of studies excluded for critical risk of bias Study ID First author Title Reason for critical bias decision 18
• 09A-3 18
• 13L-3 18
• 15M-3 18
• 16M-3 18
• 17N-3 19
• 02V-1 19
• SES socio-economic status 19
• 1. Antunes L Mazagatos C Martínez-Baz I Naesens R Borg ML Petrovic G et al. Early COVID-19 XBB.1.5 vaccine effectiveness 19
• 2. Laniece Delaunay C Melo A Maurel M Mazagatos C Goerlitz L ODonnell J et al. Effectiveness of COVID-19 vaccines 19
• 3. Ma KC Surie D Lauring AS Martin ET Leis AM Papalambros L et al. Effectiveness of Updated 20232024 Monovalent 19
• 4. Nham E Sohn JW Choi WS Wie SH Lee J Lee JS et al. Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in 19
• Korea interim analysis. Frontiers in immunology. 2024151382944. 19
• Appendix 2 VE against other COVID-19-related outcomes e.g. outpatient visits of the XBB.1.5 adapted COVID-19 vaccine compared to those who have not received the XBB.1.5 adapted COVID-19 vaccine 21
• None 21
• Appendix 3 Search strategy Medline and Embase Row Syntax 22
• NIHiCite except PubMed Syntax Filters 22
• Appendix 4 Definitions and glossary Full vaccine series 23
• Fully vaccinated Additional dose 23
• Confirmed infection Hospitalisation due to COVID-19 ICU admission due to COVID-19 Death due to COVID-19 Post-COVID-19 conditions Medically attended infection MIS-C 23
• Variants of concern VOC Vaccine effectiveness VE Relative vaccine effectiveness AZ CIs ED HCW ICU LTC LTCF MOD Obs Omicron 24
• OR PF RCT RoB UC UK USA VOI WHO 25
• Appendix 5 Critical appraisal process Low Moderate Serious Critical or No Information 26
• Low Risk of Bias indicates High Quality and Critical Risk of Bias indicates Very Low insufficient Quality 26
• Appendix 6 Data-extraction template Study details 27
• Outcomes 28
• Appendix 7a Flow chart of studies included in the current update 29
• Appendix 7b. Summary of excluded studies during full text screening new studies are in blue 30
• Author year of publication Title Reason for exclusion 30
• Appendix 7b. Summary of excluded studies during hand search new studies are in blue 32
• Author year of publication Title Reason for exclusion 32